Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine the effectiveness of AMG 162 in reducing urinary
N-telopeptide in advanced cancer subjects with bone metastases.